Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1347
http://purl.obolibrary.org/obo/NCIT_C1347
|
|---|---|
| Preferred Name | Azimexon |
| Definitions |
Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma. |
|---|---|
| prefLabel | Azimexon
|
| label | Azimexon
|
| PDQ_Closed_Trial_Search_ID | 39159
|
| code | C1347
|
| prefixIRI | NCIT:C1347
|
| in_subset | |
| Preferred_Name | Azimexon
|
| FDA_UNII_Code | 4NJ842U6BZ
|
| Contributing_Source | FDA
|
| Chemical_Formula | C9H14N4O
|
| Maps_To | Azimexon
|
| CAS_Registry | 64118-86-1
|
| NCI_Drug_Dictionary_ID | 39159
|
| Legacy Concept Name | Azimexon
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 39159
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0104835
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |